MedTrace Logo

A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects

NCT03884491 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-08-01

No results posted yet for this study

Summary

This study investigates formulations of vortioxetine applied under the tongue

Conditions

  • Healthy

Interventions

DRUG

Vortioxetine IV

an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours

DRUG

Vortioxetine SLA

5-25 mg of sublingual formulation A of vortioxetine

DRUG

Vortioxetine SLB

5-25 mg of sublingual formulation B of vortioxetine

DRUG

Vortioxetine SLC

formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-18
Primary Completion
2019-06-25
Completion
2019-07-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03884491 on ClinicalTrials.gov